Moldovan Bogdan, Saon Codin Theodor, Adam Iris-Iuliana, Pisica Radu-Mihai, Silaghi Vlad Teodor, Untaru Vlad, Stoica Doly, Crisan Madalina, Popianas Andreea, Pescaru Florentina, Zolog Adriana, Vecerzan Liliana
'St. Constantin' Hospital, 500299 Brasov, Romania.
Faculty of Medicine, "Lucian Blaga" University, 550169 Sibiu, Romania.
Diagnostics (Basel). 2024 Feb 20;14(5):455. doi: 10.3390/diagnostics14050455.
This case report details the application and outcomes of a novel therapeutic approach involving hyperthermic intraperitoneal chemotherapy (HIPEC) and hyperthermic intrathoracic chemotherapy (HITOC) in a single patient diagnosed with advanced ovarian neoplasm. The treatment protocol included pleural cytoreductive surgery (CRS) and HITOC followed by a second surgical intervention consisting of peritoneal CRS and HIPEC. HIPEC targeted the intraperitoneal space with heated chemotherapy, while HITOC extended the thermal perfusion to the thoracic cavity. The patient has shown significant progression in disease-free survival over one year and eight months of observation, demonstrating lower recurrence rates and an overall survival outcome exceeding expectations based on conventional therapy outcomes. The combined modality demonstrated a manageable toxicity profile, with no significant increase in peri- or postoperative complications observed.
本病例报告详细介绍了一种新型治疗方法在一名晚期卵巢肿瘤患者中的应用及结果,该方法包括热腹腔内化疗(HIPEC)和热胸腔内化疗(HITOC)。治疗方案包括胸膜细胞减灭术(CRS)和HITOC,随后进行第二次手术干预,包括腹膜CRS和HIPEC。HIPEC通过加热化疗靶向腹腔,而HITOC将热灌注扩展至胸腔。在一年零八个月的观察期内,患者的无病生存期有显著进展,复发率较低,总体生存结果超过基于传统治疗结果的预期。联合治疗方式显示出可管理的毒性特征,围手术期或术后并发症未显著增加。